Yizhuang Biomedical Mergers and Acquisition Funds
3
5M
3
- Areas of investment
Summary
The main department of described VC is located in the Yizhuang. The company was established in Asia in China.
The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The top activity for fund was in 2019.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Yizhuang Biomedical Mergers and Acquisition Funds, startups are often financed by Yueyin Venture Capital, Sigma Square Capital, Insight Capital. The meaningful sponsors for the fund in investment in the same round are Sigma Square Capital, Juren Capital, Insight Capital.
Among the most popular fund investment industries, there are Biotechnology, Health Diagnostics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most popular portfolio startups of the fund, we may highlight GenomePrecision. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Investments by industry
- Health Diagnostics (2)
- Biotechnology (2)
- Health Care (2)
- Medical (1)
- Biopharma (1)
- Investments by region
-
- China (3)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Green Bamboo Bio | 30 Jun 2022 | Biotechnology, Health Care, Health Diagnostics, Medical, Biopharma | Late Stage Venture | Beijing, Beijing, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.